Choosing the Right Candidates for Remote Monitoring-Video - Choosing the Right Candidates for Remote Monitoring

Video - Choosing the Right Candidates for Remote Monitoring

Video Transcription

Video Summary

The speaker reviews how to select heart failure patients for remote monitoring with implantable pulmonary artery pressure (PAP) sensors. Evidence from randomized trials, observational studies, and meta-analyses shows PAP-guided management is safe and reduces heart failure hospitalizations by about 30% to 35%, while also lowering pressures and improving quality of life in both HFrEF and HFpEF.  <br /><br />The FDA first approved CardioMEMS in 2014 for NYHA class III patients hospitalized for heart failure in the prior year, with inability to take antiplatelet/anticoagulant therapy as the main contraindication. In 2022, the indication expanded to NYHA class II or III patients with recent hospitalization or elevated BNP/NT-proBNP. A newer system, Cordella, was approved in 2024 for stable NYHA class III patients on diuretics and GDMT.  <br /><br />Case examples emphasize ruling out patients who need CRT or mitral TEER first; otherwise, eligible patients should be considered for PAP-guided management.

Keywords

heart failure

pulmonary artery pressure sensors

remote monitoring

CardioMEMS

Cordella